These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 9918205)

  • 1. Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies.
    Yao TJ; Meyers M; Livingston PO; Houghton AN; Chapman PB
    Clin Cancer Res; 1999 Jan; 5(1):77-81. PubMed ID: 9918205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside.
    Chapman PB; Williams L; Salibi N; Hwu WJ; Krown SE; Livingston PO
    Vaccine; 2004 Jul; 22(21-22):2904-9. PubMed ID: 15246627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.
    McCaffery M; Yao TJ; Williams L; Livingston PO; Houghton AN; Chapman PB
    Clin Cancer Res; 1996 Apr; 2(4):679-86. PubMed ID: 9816218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.
    Chapman PB; Wu D; Ragupathi G; Lu S; Williams L; Hwu WJ; Johnson D; Livingston PO
    Clin Cancer Res; 2004 Jul; 10(14):4717-23. PubMed ID: 15269144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin.
    Grant SC; Kris MG; Houghton AN; Chapman PB
    Clin Cancer Res; 1999 Jun; 5(6):1319-23. PubMed ID: 10389914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines.
    Helling F; Shang A; Calves M; Zhang S; Ren S; Yu RK; Oettgen HF; Livingston PO
    Cancer Res; 1994 Jan; 54(1):197-203. PubMed ID: 8261439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.
    Ragupathi G; Meyers M; Adluri S; Howard L; Musselli C; Livingston PO
    Int J Cancer; 2000 Mar; 85(5):659-66. PubMed ID: 10699946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
    Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
    Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer.
    Dickler MN; Ragupathi G; Liu NX; Musselli C; Martino DJ; Miller VA; Kris MG; Brezicka FT; Livingston PO; Grant SC
    Clin Cancer Res; 1999 Oct; 5(10):2773-9. PubMed ID: 10537341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.
    Chapman PB; Morrissey DM; Panageas KS; Hamilton WB; Zhan C; Destro AN; Williams L; Israel RJ; Livingston PO
    Clin Cancer Res; 2000 Mar; 6(3):874-9. PubMed ID: 10741710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
    Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
    Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.
    Helling F; Zhang S; Shang A; Adluri S; Calves M; Koganty R; Longenecker BM; Yao TJ; Oettgen HF; Livingston PO
    Cancer Res; 1995 Jul; 55(13):2783-8. PubMed ID: 7796403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines.
    Livingston PO
    Immunol Rev; 1995 Jun; 145():147-66. PubMed ID: 7590824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody.
    Chapman PB
    Curr Opin Investig Drugs; 2003 Jun; 4(6):710-5. PubMed ID: 12901230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ganglioside vaccines with emphasis on GM2.
    Livingston P
    Semin Oncol; 1998 Dec; 25(6):636-45. PubMed ID: 9865678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin.
    Chapman PB; Morrisey D; Panageas KS; Williams L; Lewis JJ; Israel RJ; Hamilton WB; Livingston PO
    Clin Cancer Res; 2000 Dec; 6(12):4658-62. PubMed ID: 11156217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: enhancement of immunogenicity of anti-idiotypic monoclonal antibody MK2-23 by fusion with interleukin 2.
    Wang X; Ko EC; Peng L; Gillies SD; Ferrone S
    Cancer Res; 2005 Aug; 65(15):6976-83. PubMed ID: 16061683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.
    Ragupathi G; Cappello S; Yi SS; Canter D; Spassova M; Bornmann WG; Danishefsky SJ; Livingston PO
    Vaccine; 2002 Jan; 20(7-8):1030-8. PubMed ID: 11803062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).
    Giaccone G; Debruyne C; Felip E; Chapman PB; Grant SC; Millward M; Thiberville L; D'addario G; Coens C; Rome LS; Zatloukal P; Masso O; Legrand C
    J Clin Oncol; 2005 Oct; 23(28):6854-64. PubMed ID: 16192577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette-Guérin (BCG) instillation on carcinoma in situ of the urinary bladder.
    Jurincic-Winkler C; Metz KA; Beuth J; Sippel J; Klippel KF
    Anticancer Res; 1995; 15(6B):2771-6. PubMed ID: 8669862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.